N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate
- PMID: 16624894
- DOI: 10.1093/glycob/cwj117
N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate
Abstract
Dermatan sulfate (DS) accelerates the inhibition of thrombin by heparin cofactor II (HCII). A hexasaccharide consisting of three l-iduronic acid 2-O-sulfate (IdoA2SO3)-->N-acetyl-D-galactosamine 4-O-sulfate (GalNAc4SO3) subunits was previously isolated from porcine skin DS and shown to bind HCII with high affinity. DS from porcine intestinal mucosa has a much lower content of this disaccharide but activates HCII with potency similar to that of porcine skin DS. Therefore, we sought to characterize oligosaccharides from porcine mucosal DS that interact with HCII. DS was partially depolymerized with chondroitinase ABC, and oligosaccharides containing 2-12 monosaccharide units were isolated. The oligosaccharides were then fractionated by anion-exchange and affinity chromatography on HCII-Sepharose, and the disaccharide compositions of selected fractions were determined. We found that the smallest oligosaccharides able to bind HCII were hexasaccharides. Oligosaccharides 6-12 units long that lacked uronic acid (UA)2SO3 but contained one or two GalNAc4,6SO3 residues bound, and binding was proportional to both oligosaccharide size and number of GalNAc4,6SO3 residues. Intact DS and bound dodecasaccharides contained predominantly IdoA but little D-glucuronic acid. Decasaccharides and dodecasaccharides containing one or two GalNAc4,6SO3 residues stimulated thrombin inhibition by HCII and prolonged the clotting time of normal but not HCII-depleted human plasma. These data support the hypothesis that modification of IdoA-->GalNAc4SO3 subunits in the DS polymer by either 2-O-sulfation of IdoA or 6-O-sulfation of GalNAc can generate molecules with HCII-binding sites and anticoagulant activity.
Similar articles
-
Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity.J Biol Chem. 1990 Oct 25;265(30):18263-71. J Biol Chem. 1990. PMID: 2211700
-
Structural characterization and antithrombin activity of dermatan sulfate purified from marine clam Scapharca inaequivalvis.Glycobiology. 2009 Apr;19(4):356-67. doi: 10.1093/glycob/cwn140. Epub 2008 Dec 4. Glycobiology. 2009. PMID: 19056786
-
Active site for heparin cofactor II in low molecular mass dermatan sulfate. Contribution to the antithrombotic activity of fractions with high affinity for heparin cofactor II.Thromb Res. 1996 Oct 1;84(1):21-32. doi: 10.1016/0049-3848(96)00158-2. Thromb Res. 1996. PMID: 8885144
-
The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide.Adv Exp Med Biol. 1992;313:167-76. doi: 10.1007/978-1-4899-2444-5_17. Adv Exp Med Biol. 1992. PMID: 1442260 Review.
-
The interaction of glycosaminoglycans with heparin cofactor II.Ann N Y Acad Sci. 1994 Apr 18;714:21-31. doi: 10.1111/j.1749-6632.1994.tb12027.x. Ann N Y Acad Sci. 1994. PMID: 8017769 Review.
Cited by
-
LC-MS and LC-MS/MS studies of incorporation of 34SO3 into glycosaminoglycan chains by sulfotransferases.Glycobiology. 2013 Aug;23(8):969-79. doi: 10.1093/glycob/cwt033. Epub 2013 May 21. Glycobiology. 2013. PMID: 23696150 Free PMC article.
-
Mice deficient in N-acetylgalactosamine 4-sulfate 6-o-sulfotransferase are unable to synthesize chondroitin/dermatan sulfate containing N-acetylgalactosamine 4,6-bissulfate residues and exhibit decreased protease activity in bone marrow-derived mast cells.J Biol Chem. 2010 Jul 2;285(27):20793-805. doi: 10.1074/jbc.M109.084749. Epub 2010 May 3. J Biol Chem. 2010. PMID: 20439988 Free PMC article.
-
Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin.Glycobiology. 2019 Jun 1;29(6):446-451. doi: 10.1093/glycob/cwz019. Glycobiology. 2019. PMID: 30869126 Free PMC article.
-
Oral administration of dermatan sulphate reduces venous thrombus formation in vivo: potential use as a formulation for venous thromboembolism.Inflammopharmacology. 2021 Apr;29(2):525-535. doi: 10.1007/s10787-020-00771-x. Epub 2020 Nov 23. Inflammopharmacology. 2021. PMID: 33230702
-
Specific sides to multifaceted glycosaminoglycans are observed in embryonic development.Semin Cell Dev Biol. 2010 Aug;21(6):631-7. doi: 10.1016/j.semcdb.2010.06.002. Epub 2010 Jul 3. Semin Cell Dev Biol. 2010. PMID: 20599516 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources